Again, NSCLC patients responding to programmed cell death protein 1 (PD‐1) antibody therapy were found to have higher baseline levels of fecal SCFAs concentration (Zizzari et al, 2020). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.